Tumor tissue test may guide ovarian cancer drug choices

NCT ID NCT03877796

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 35 times

Summary

This study is for people with advanced ovarian cancer whose disease has stopped responding to platinum-based chemotherapy. Researchers will collect archived tumor tissue to test a method called DRP, which aims to predict whether certain investigational cancer drugs might be effective for that individual. The goal is to better match patients with treatments they are likely to benefit from, and to learn from past treatments. About 60 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beatson West of Scotland Cancer Centre

    ACTIVE_NOT_RECRUITING

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Dana-Farber Cancer Institute

    COMPLETED

    Boston, Massachusetts, 02215, United States

  • Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital

    ACTIVE_NOT_RECRUITING

    London, United Kingdom

  • OU Health Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Swedish Center for Research and Innovation

    RECRUITING

    Seattle, Washington, 98122, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.